Q-omics provides the consensus-scored LGR5 profile across patient tissues and cancer cell-line models. LGR5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LGR5 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, LGR5 RNA expression shows 16,092 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, COAD, and THYM as cancer lineages where LGR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGR5 survival associations across molecular data types. LGR5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGR5 RNA expression–survival associations across cancer types. High LGR5 expression shows unfavorable associations in ACC, KIRP and SCLC, but favorable associations in HNSC, LUAD and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LGR5 RNA expression.
This table summarizes LGR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LGR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGR5 shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in COAD, STAD and BLCA. The COAD box plot shows higher LGR5 RNA expression in tumor versus normal tissue (log2 FC = +2.596, t-test p < 0.001).
This table shows molecular features associated with LGR5 in patient tissues and cancer cell lines. In patient samples, LGR5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LGR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
